In a recently published Chinese primary treatment RCTS study, triple combination therapy with an ICI (tislelizumab) and an oral anticancer drug (S-1) demonstrated a high ORR of 92.1% and a median PFS of 12.6 months in patients with HER2-positive gastric cancer, raising expectations for further research [42,43]. This evidence concerns the gene ERBB2 and gastric cancer.